Press Release

The HCS training course at Institut Pasteur Korea (IPK) certified the official Pasteur International Courses (PIC-label)

The HCS training course at Institut Pasteur Korea (IPK) certified 
the official Pasteur International Courses (PIC-label)
- Certification of world-class new drug development specialized training program -
- Fosters drug development experts and contributes to the bio-ecosystem to address public health issues -
Institut Pasteur Korea(IPK) announced that IPK's annual regular training course, 'High-Content Screening (HCS) for Therapeutics Discovery' course, has obtained the official Pasteur International Courses (PIC) Label.

The PIC label is an international training course certification awarded by the Pasteur Network to world-class courses and which recognizes their excellence. 


IPK will foster drug development experts who can respond to emerging infectious diseases and other related areas through the HCS course and spread a advanced technologies.

HCS course provides theoretical and practical training for the discovery of new drug candidates, mentoring by expert instructors from the Pasteur Network, and opportunities for global exchange.
Participants are offered various training on advanced screening technologies, including cell-based assay development, automated microscopy utilization, and low-content/high-content screening over a 5-day period.

Participants of various levels (MS students, PhD, Post-doc researchers, senior researchers)  from domestic and international institutions, including the Pasteur Network, the Korea National Institute of Health (KNIH), Harvard Medical School Boston's Children's Hospital, the Daegu-Gyeongbuk Medical Cluster (K-MEDIhub), and others, attended this year's course. In total, 20 participants from 6 different countries completed the course.

IPK is planning to conduct a HCS course in August next year and intends to select around 20 participants in June of the same year. 

The course is open to graduate students, postdoctoral researchers, and others  who plan to use HCS technology, implement screening capacity in their research center. Participants will be selected through a document review process by the internal operating committee of IPK.

Byungkwon Lim, CEO of IPK, said, “Leveraging the cell-based assays and screening technology, IPK successfully discovered new drug candidates for various diseases. We have been keen to disseminate our technology and know-how throughout over 5 HCS sessions in the past, and will put continued efforts to contribute to the development of experts and the creation of a bio-ecosystem.”

The PIC label will be effective for 3 years and upon expiry IPK will reapply.